CRSP - CRISPR Therapeutics AG
(NaN%)
Sell
Weak Growth●Earnings/Profit is Negative
27%
based on last 5 year data.
Income Statement is WEAK
Revenue Growth is -99.75%
Operating Income is Negative
Net Income is Negative
Earnings Per Share (EPS) is Negative
Net Margin is -48520.86%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 18.21
Debt Ratio is 0.09
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.0
Cash Flow is WEAK
Cash from Operations is Negative
Capital Expenditure not available
Net Increase in Cash is Positive
Long Term Score Trend is NEGATIVE
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
CRISPR Therapeutics AG (CRSP) - http://www.crisprtx.com/about-us/contact
Exchange - NASDAQ/NMS (GLOBAL MARKET)
Industry - Biological Product (except Diagnostic) Manufacturing
Sector - Manufacturing
CEO - Samarth Kulkarni
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.
Know the Stock © 2021 and future.